Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patients
The Journal of Sexual Medicine · 2025
DOI: 10.1093/jsxmed/qdaf164 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Bruno Chiesa G Nascimento und 12 weiteren Autor:innen. Beteiligte Einrichtung: Divisão de Urologia, Hospital das Clínicas-Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 255, Cerqueira César…. Hauptthemen laut MEDLINE: Testosterone, Prostatic Neoplasms, Prostatectomy, Androgen Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Janssen Research and Development.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Recovery of endogenous testosterone following androgen deprivation therapy (ADT) for prostate cancer is uncertain.
Aim
To prospectively evaluate testosterone (T) recovery rates and timing after neoadjuvant ADT followed by radical prostatectomy (RP).
Methods
We report a secondary analysis from a phase II randomized trial involving 64 patients who received a 3-month neoadjuvant ADT regimen (goserelin, abiraterone with prednisone and for half of the participants, apalutamide) followed by RP. Total Testosterone (TT) was measured at baseline, during ADT (3 m), and after 4, 8, and 12 months post-ADT cessation. Return to non-castrate levels (TT > 50 ng/dL), to normal (TT ≥ 300 ng/dL), and back to baseline level (BTB, defined as TT ≥ baseline) are reported. Predictive factors were analyzed using uni and multivariate analyses (MVA), and quality of life (QoL) was assessed with the validated Expanded Prostate Cancer Index Composite (EPIC-50). Outcomes Chance and chronology of T recovery 1 year after ADT cessation.
Results
Median T levels were as follows: baseline 442 ng/dL (IQR: 321–505); 4 months post-ADT, 144 ng/dL (IQR: 35–284); 8 months, 316 ng/dL (IQR: 243–438); and 12 months, 358 ng/dL (IQR: 285–477). By 12 months, 98.1% of patients reached non-castrate levels, 79.5% returned to normal, and 33.9% to BTB. Half of the patients achieved T > 50 ng/dL in 5 months, T ≥ 300 ng/dL in 9.1 months, and BTB in 13.1 months. In MVA, baseline T was the only significant predictor for T normalization (OR: 1.015; P < .01), while age and baseline T were predictors for BTB recovery (OR for age: 0.88; P = .02; OR for baseline T: 0.99; P = .02). QoL assessment showed persistently low sexual function, with minor improvements over time (median scores: 0 [0–5.6] at 4 months and 2.8 [0–29.2] at 12 months, P < .01), while sexual bother starts very low but significantly increases during follow up (median scores: 100 [IQR: 42.2–100] at 4 months to 50 [IQR: 0–100] at 12 months, P = .03). Clinical Implications Long-term lower T levels can occur even after short-term ADT, persisting longer than anticipated. Clinicians should consider this in patient management. Strengths and Limitations Our strengths include the prospective, controlled design and a rarely reported ADT triple therapy followed by RP. Limitations include the use of immunoassay to measure TT.
Conclusion
After 3 months of neoadjuvant triple ADT and RP, significant recovery to non-castrate and normal T levels is seen in most patients by 1 year; yet, BTB recovery is achieved in only a third. Higher baseline T and younger age predict faster T normalization and BTB recovery, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Divisão de Urologia, Hospital das Clínicas-Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 255, Cerqueira César, São Paulo - SP - CEP 05403-000, Brazil.
- Divisão de Urologia, Universidade Estadual de Feira de Santana, Avenida Transnordestina, s/n, Novo Horizonte, Feira de Santana - Bahia - CEP 44036-900, Brazil.
- Centro de Oncologia, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 115, Bela Vista, São Paulo - SP, CEP 01308-050, Brazil.
- Sexual & Reproductive Medicine Program, Urology Service, Memorial SloanKettering Cancer Center, 205 E 64th St, New York, NY 10022, USA.
ORCID-Profile: Bruno Chiesa G Nascimento, José Bessa Junior, Eduardo de P Miranda
Förderung
- Janssen Research and Development
Zitieren
APA
Nascimento, B. C. G., Pedrenho, R., Zandoná, P. C. E., Sanvido, L. V., Bessa Junior, J., Miranda, E. P., Bastos, D. A., Cordeiro, M. D., Coelho, R., Nahas, W. C., Hallak, J., Mulhall, J. P., & Gomes, C. M. (2025). Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patients. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf164
Vancouver
Nascimento BCG, Pedrenho R, Zandoná PCE, Sanvido LV, Bessa Junior J, Miranda EP, et al. Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patients. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf164
BibTeX
@article{Nascimento2025,
author = {Nascimento, Bruno Chiesa G and Pedrenho, Rubens and Zandoná, Pedro C E and Sanvido, Lucas V and Bessa Junior, José and Miranda, Eduardo de P and Bastos, Diogo A and Cordeiro, Mauricio D and Coelho, Rafael and Nahas, William C and Hallak, Jorge and Mulhall, John P and Gomes, Cristiano M},
title = {Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patients},
journal = {The Journal of Sexual Medicine},
year = {2025},
doi = {10.1093/jsxmed/qdaf164}
}
EUVIMED